Table 2.

Clinical features of NMOSD cases and MS controls.

Clinical feature	NMOSD	MS	p-value
N	67	100
Age (years)–median (range)	49 (19–85)	46 (16–73)	ns
Sex (Female)–n/N (%)	60/67 (90)	85/100 (85)	ns
Age at Onset (Years)–median (range)	41 (13–85)	32 (6–59)	<0.001
Disease Duration (Years)–median (range)	3.8 (0.1–43.1)	12.1 (0.5–43.4)	<0.001
Relapses–median (range)	4 (1–16)	3 (0–11)	ns
Annualised relapse rate–mean (SD)	0.78 (0.17–3.33)	0.33 (0.06–3.78)	<0.001
EDSS–median (range)	4 (0–9)	2 (0–9)	<0.001
Clinical Course–n (%)			0.016*
Monophasic (CIS)	9 (13)	12 (12)
Relapsing remitting	56 (84)	73 (73)
Secondary progressive	2 (3)	13 (13)
Primary progressive	0 (0)	2 (2)
CSF protein elevation–n/N (%)	19/42 (45)	3/39 (8)	<0.001
CSF white cell count elevation–n/N (%)	18/35 (51)	4/36 (11)	<0.001
Local synthesis of OCB–n/N (%)	8/42 (19)	29/40 (73)	<0.001

NMOSD, neuromyelitis optica spectrum disorders; MS, multiple sclerosis; SD, standard deviation; EDSS, expanded disability status scale; CIS, clinically isolated syndrome; CSF, cerebrospinal fluid; OCB, oligoclonal bands.

^*Overall comparison of all four groups.